BioNeutral Group Completes Required Good Laboratory Practice (GLP) Testing for Ygiene™

Bioneutral Is Ready to File for EPA Review for Registration of Its Ygiene™ Hospital-Grade Disinfectant and Begins to Focus Commercial Efforts in Europe Where Approvals Have Already Been Obtained

BioNeutral Group, Inc. (OTCBB:BONU), a specialty chemical technology-based life science company, reports that it has completed the required Independent Good Laboratory Practice (GLP) toxicity, chemistry and efficacy testing required for submission of its Ygiene™ Hospital Disinfectant to the U.S. Environmental Protection Agency (EPA). Based upon the completion of these required tests, the Company will be filing for EPA review of its Ygiene™ Hospital Disinfectant in the near future after consulting with its advisers.

As the Company prepares to submit for registration from the EPA, a key step in the eventual marketing and sales of Ygiene™ within the U.S., it is also focusing its commercial efforts in Europe, where approvals have already been obtained or are in the process of being secured. The Company has approval for Ygiene™ platform sales as a antimicrobial within Germany and has received legal advice on same sales within the United Kingdom, France and Sweden.

Dr. Andy Kielbania, Chief Scientist for BioNeutral, stated: “We are very pleased with the positive results of our independent GLP testing required for submission to the EPA. This is a significant milestone achievement for our technology. It provides further evidence of the quality and effectiveness of Ygiene™ as a disinfectant, and of course it assists in our eventual goal of sales within the U.S.”

About BioNeutral Group, Inc.
Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a specialty chemical technology-based life science company that is developing and intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous microorganisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene™ and Ogiene™, are both eco-friendly. The Company has combined these widely used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral’s proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene™ brand have not yet been submitted to the EPA for approval for sale in the United States; however they have been approved in Germany and are allowed in the UK, France and Sweden.

Forward-Looking Statements
BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene™ and are not yet available for sale in the United States.

Source: Business Wire/Yahoo Finance